Metrochem API Private Limited Metrochem API Private Limited

X

Find the latest Drugs in Development and Pipeline Prospector News of Nobelpharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Nobelpharma
japan Flag
Country
Country
Japan
Address
Address
Shinkawa, Chuo-ku, Tokyo 104-0033
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Sargmalin (sargramostim) is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF). It is approved for the treatment of autoimmune pulmonary alveolar proteinosis.


Lead Product(s): Sargramostim

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Sargmalin

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Partner Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Hyftor (sirolimus) is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in patients with age of 6 years and older. Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines.


Lead Product(s): Sirolimus

Therapeutic Area: Rare Diseases and Disorders Product Name: Hyftor

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

HYFTOR™ (sirolimus topical gel) 0.2% is the first and only clear topical medication approved by the FDA to treat facial angiofibroma associated with TSC in adults and children 6 years of age and older.


Lead Product(s): Sirolimus

Therapeutic Area: Rare Diseases and Disorders Product Name: Hyftor

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 30, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

HYFTOR™ (sirolimus topical gel) 0.2% is the first and only clear topical medication approved by the FDA to treat facial angiofibroma associated with TSC in adults and children 6 years of age and older.


Lead Product(s): Sirolimus

Therapeutic Area: Rare Diseases and Disorders Product Name: Hyftor

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 25, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Hyftor (sirolimus) 0.2% is the first and only clear topical medication approved by the FDA to treat facial angiofibroma associated with TSC in adults and children 6 years of age and older.


Lead Product(s): Sirolimus

Therapeutic Area: Rare Diseases and Disorders Product Name: Hyftor

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 04, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY